Formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or class II molecules for vaccines

A pharmaceutical composition comprising:

• (a) at least 2 peptides;
• wherein said at least 2 peptides comprise SEQ ID NO:
• 5 and SEQ ID NO:
• 13, respectively;
• each peptide has a length of between 8 and 16 amino acids;
• wherein said peptides show a solubility in 90% acetic acid of at least 2.7 mg/mL;
• and
• (b) mannitol and poloxamer 188 or mannitol and polyoxyethylene (20) sorbitan monooleate, wherein the ratio by weight of said peptides to mannitol to poloxamer 188 is in the range including and between 1:5:1.5 to 1:8:2.2 or including and between 1:0:2 to 1:0:2.2;
• or wherein the ratio by weight of said peptides to mannitol to polyoxyethylene (20) sorbitan monooleate is in the range including and between 1:2:1.5 to 1:8:2.2.